Cognetivity Neurosciences (CSE: CGN) this morning announced that it has seen another publication of a scientific paper on its assessment tool for early-stage Alzheimer’s. Referred to by the company as an Integrated Cognitive Assessment, or ICA, the firm indicates that the peer-reviewed paper provides further evidence of the benefits of the tool.
The paper itself reportedly demonstrates the “sensitivity to early-stage Alzheimer’s Disease, freedom from cultural or educational bias and suitability for remote patient monitoring,” that the assessment tool offers. Furthermore, it further validates the use of the tool as a digital cognitive biomarker, which is effective at identifying mild cognitive impairment and Alzheimer’s disease, particularly at mild or early stages.
One of the key benefits of the ICA, as outlined within the scientific paper, is that the platform performs consistently in international populations, where traditionally there have been limitations due to language and culture-specific data. The result is that the tool can be effectively deployed at scale rapidly, without the need to collect additional data.
Sponsored · First Phosphate Corp.
Lastly, it was also highlighted that the tool works excellent as a remote cognitive assessment, without the loss of testing accuracy. This feature in particular makes the platform an excellent option for high-frequency monitoring both at clinics and at home.
The diagnostic accuracy of the ICA and its novel use of explainable AI, combined with the power to generalize across other languages and cultures, make it uniquely suitable for cognitive screening across large and diverse populations. And in light of the FDA’s recent approval of the disease-modifying drug aducanumab, the need for a device capable of screening a wide population of at-risk individuals has never been higher.
Professor Dag Aarsland, co-author of the scientific paper
The full scientific paper can be reviewed here.
Cognetivity Neurosciences last traded at $1.07 on the CSE.
FULL DISCLOSURE: Cognetivity Neurosciences Ltd is a client of Canacom Group, the parent company of The Deep Dive. The author has been compensated to cover Cognetivity Neurosciences Ltd on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.
